Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.The partnership leverages IBM’s foundation model technologies, consisting of…
Continue Reading
Vivodyne started as an idea between Co-Founders Andrei Georgescu (left), now Vivodyne’s CEO, and UPenn Professor Dan Huh (right), now Vivodyne’s CSO, while Andrei performed his Ph.D. graduate studies in Huh’s bioengineering research lab….
Continue Reading
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT THEY DO
Vivodyne is…
What You Should Know:
– Genentech and NVIDIA today announced a multi-year strategic research collaboration that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing…
Continue Reading
Sabrina Steffen, Head of Data Strategy and Innovation for Data Management at IQVIA
In drug development, there is a critical focus on protocol design, because it is a key component to running a successful clinical…
Continue Reading
What You Should Know:
Pepper Bio, the “Google Maps for drug discovery,” today announced an oversubscribed $6.5 million seed round led by NFX with participation from Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, VSC Ventures,…
Continue Reading
What You Should Know:
– Classiq, NVIDIA, and Tel Aviv Sourasky Medical Center have established a new initiative, the Quantum Computing for Life Sciences & Healthcare Center, to develop and implement quantum algorithms and applications…
Continue Reading
The pace at which generative AI has infiltrated product portfolios and media headlines in 2023 has brought excitement and consternation to those tasked with evaluating its implications for patient care. Owen Hughes reportsWhile AI…
Continue Reading
Global healthcare investment firm OrbiMed announced it raised more than $4.3 billion in commitments for its private investment funds–OrbiMed Asia Partners V, OrbiMed Royalty & Credit Opportunities IV and OrbiMed Private Investments IX.A range…
Continue Reading
